164 related articles for article (PubMed ID: 19671594)
21. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
Wu MJ; Chang CH; Shu KH; Ho HC; Li JR; Fu YC
Transplant Proc; 2014 May; 46(4):1226-8. PubMed ID: 24815166
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Gutiérrez MJ; González E; Andrés A; Morales JM
Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
[TBL] [Abstract][Full Text] [Related]
23. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy.
Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Takeuchi S; Tomioka M; Shigehara T; Maeshima A; Kaneko Y; Hiromura K; Kopp JB; Nojima Y
Nephrol Dial Transplant; 2009 Aug; 24(8):2378-83. PubMed ID: 19188342
[TBL] [Abstract][Full Text] [Related]
24. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
25. Newly identified cytoskeletal components are associated with dynamic changes of podocyte foot processes.
Miao J; Fan Q; Cui Q; Zhang H; Chen L; Wang S; Guan N; Guan Y; Ding J
Nephrol Dial Transplant; 2009 Nov; 24(11):3297-305. PubMed ID: 19617259
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus damages podocytes in rats with protein overload nephropathy.
Cai Y; Chen Y; Zheng S; Chen B; Yang Y; Xia P
J Nephrol; 2011; 24(3):307-12. PubMed ID: 20954132
[TBL] [Abstract][Full Text] [Related]
27. Synaptic vesicle protein 2B is expressed in podocyte, and its expression is altered in proteinuric glomeruli.
Miyauchi N; Saito A; Karasawa T; Harita Y; Suzuki K; Koike H; Han GD; Shimizu F; Kawachi H
J Am Soc Nephrol; 2006 Oct; 17(10):2748-59. PubMed ID: 16943307
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin attenuates the severity of murine adriamycin nephropathy.
Lui SL; Tsang R; Chan KW; Zhang F; Tam S; Yung S; Chan TM
Am J Nephrol; 2009; 29(4):342-52. PubMed ID: 18948688
[TBL] [Abstract][Full Text] [Related]
29. The role of podocytes in glomerular pathobiology.
Asanuma K; Mundel P
Clin Exp Nephrol; 2003 Dec; 7(4):255-9. PubMed ID: 14712353
[TBL] [Abstract][Full Text] [Related]
30. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
31. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
32. Protective Effect of Salvia Przewalskii Extract on Puromycin-Induced Podocyte Injury.
Dai DS; Liu X; Yang Y; Luo XM; Tang RX; Yin ZC; Ren HQ
Am J Nephrol; 2015; 42(3):216-27. PubMed ID: 26439819
[TBL] [Abstract][Full Text] [Related]
33. Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
Shen X; Zhang Y; Lin C; Weng C; Wang Y; Feng S; Wang C; Shao X; Lin W; Li B; Wang H; Chen J; Jiang H
J Pathol; 2020 Nov; 252(3):227-238. PubMed ID: 32686149
[TBL] [Abstract][Full Text] [Related]
34. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin reduces proteinuria and renal damage in the rat remnant kidney model.
Esposito C; Villa L; Grosjean F; Mangione F; Esposito V; Castoldi F; Serpieri N; Arra M; Pertile E; Maggi N; Valentino R; Dal Canton A
Transplant Proc; 2009 May; 41(4):1370-1. PubMed ID: 19460562
[TBL] [Abstract][Full Text] [Related]
36. Semi-automated quantitative image analysis of podocyte desmin immunoreactivity as a sensitive marker for acute glomerular damage in the rat puromycin aminonucleoside nephrosis (PAN) model.
Herrmann A; Tozzo E; Funk J
Exp Toxicol Pathol; 2012 Jan; 64(1-2):45-9. PubMed ID: 20591637
[TBL] [Abstract][Full Text] [Related]
37. Selective albuminuria via podocyte albumin transport in puromycin nephrotic rats is attenuated by an inhibitor of NADPH oxidase.
Kinugasa S; Tojo A; Sakai T; Tsumura H; Takahashi M; Hirata Y; Fujita T
Kidney Int; 2011 Dec; 80(12):1328-38. PubMed ID: 21849973
[TBL] [Abstract][Full Text] [Related]
38. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases.
Ikezumi Y; Suzuki T; Karasawa T; Kawachi H; Nikolic-Paterson DJ; Uchiyama M
Biochem Biophys Res Commun; 2008 Nov; 376(4):706-11. PubMed ID: 18809387
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of glomerular visceral epithelial cell endocytosis during nephrosis induced by puromycin aminonucleoside.
Schwartz MM; Sharon Z; Pauli BU; Lewis EJ
Lab Invest; 1984 Dec; 51(6):690-6. PubMed ID: 6389977
[TBL] [Abstract][Full Text] [Related]
40. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.
Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P
J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
